High-Impact Cancer Research 2019 is a course dedicated to the wide spectrum of cancer science and the skills necessary to envision, design, and lead cutting-edge cancer research.
Topics
- Characteristic Biology of Tumors and Cancer Cells
- Oncogenes and signal transduction
- Cell proliferation and cell cycle control
- P53 And Li-Fraumeni syndrome
- Inherited predisposition
- Programmed cell death
- Epigenetics
- Tumor microenvironment
- Mitochondria and metabolism
- Protein homeostasis and autophagy
- Invasion and metastasis (EMT)
- Non-coding RNAs and cancer
- Tumor heterogeneity and clonal evolution
- RNA expression profiles
- Mutational signatures
- The Cancer Problem
- Introduction to clinical cancer problems
- The worldwide cancer problem
- Introduction to cancer epidemiology
- Neoplasia and the pathology of cancer
- The ten most important cancer research papers published in the past year
- Introduction to cancer therapy
- Hallmarks of cancer, a central paradigm of cancer biology
- State-of-the-Art Approaches to Cancer Study
- Zebrafish models of cancer
- Animal models: from mouse to man
- Human tumor models
- Cell Llnes, NCI 60, CCLE, and newly derived lines
- Prevention and Risk Identification
- Environmental carcinogenesis
- Epidemiology and cancer risk identification
- Global tobacco epidemic
- Diet, obesity, and cancer
- HPV vaccine and how it works
- Tobacco control strategies
- Potential impact of the oncovirus vaccine across the globe
- Immunotherapy
- Immunogenomics: neoantigens to vaccines
- Immunology as a basis to understand immunotherapy
- Clinical trials for immunotherapy
- Rational targeting of Hodgkin disease with immuno-oncology approaches
- Immuno-oncology aspects and function of myeloid cells
- Mouse models for immunotherapeutics
- Discovery of novel targets for cancer immunotherapy
- CAR-T Cells
- Next-generation immunotherapy companies
- T cell exhaustion
- Therapy and Drug Development
- Surgical therapy
- Cytotoxics
- Pharmacodynamics
- Radiation therapy
- Small molecule discovery and chemical biology
- Pharmacokinetics
- Government oversight
- Clinical trials: IRB, Phase I, II, and III
- From -Omics to target identification
- Challenges and opportunities in development of molecularly-defined basket trials
- Opportunities and challenges in developing first-in-class innovative agents
- Drug discovery: nanotechnology, targeting, and RNA therapeutics
- Antibody-based therapeutics in oncology
- Development of biomarkers for precision cancer medicine
- Therapeutic targeting of ubiquitin ligase activity
- Innovation: new therapeutic strategies
- Role of venture capital in the creation of new oncology therapeutics companies
- Polymeric nanoparticles: tumor microenvironment variability and implications for new nanoparticle design and development
- Case Studies:
- Breast Cancer
- Clinical predispositions to breast and ovarian cancer
- Cellular and molecular heterogeneity in breast cancer
- Breast cancer triple negative
- Breast cancer screening
- Hormone-responsive breast cancer
- HER2-driven breast cancer
- Disparities in breast cancer
- Breast cancer metastasis and metastatic niches
- Infection from Carcinogenic Organisms
- Viral oncology: RNA viruses and oncogenes
- Infectious causes of cancer overview
- EBV: the first human cancer virus
- Viral oncology: DNA viruses and tumor suppressor genes
- Hepatocellular cancer: the role of viruses and inflammation
- Lung Cancer
- Genomic approaches in lung cancer
- Introduction to lung cancer
- Lung cancer: resistance to targeted therapies and impact on therapeutic strategies
- Identifying and overcoming resistance to therapy in cancers
- RAS, lung cancer, and the hunt for new therapeutic strategies
- Combination therapies in lung cancer
- Cervical Cancer
- Cervical cancer: clinical perspectives
- Cervical cancer: historical perspectives
- Cervical cancer screening
- Leukemia and Lymphoma
- Hematological disorders
- Hematological malignancies
- Hematological stem cells
- Transplantation therapies
- The leukemic niche
- Leukemia-initiating cells
- Myeloid neoplasms (AML, MDS, Pmpns)
- Targeted therapy: CML and Gleevec
- CLL
- Role of genetics and clonal evolution
- Plasma cell neoplasms
- B-cell lymphomas (including Hodgkin lymphoma)
- Childhood Leukemia and Young Adult Solid Tumors
- Young adult cancers
- Childhood leukemia
- Melanoma
- DNA damage and repair
- Melanoma
- Immunotherapy in melanoma
- BRAF therapy
- Colon Cancer
- Progression and tumor evolution
- Clinical introduction to colon cancer
- Screening for colon cancer
Who should Attend
- Clinical Researchers
- Basic Researchers
- Leaders of Cancer-Focused Organizations: Scientific, Policy, and Financial
- Population Researchers
- Top-Flight Trainees
